You are an expert biomedical scientific-writing reviewer performing a rigorous peer-review-style evaluation.

Your job: score the candidate model's generated "Abstract" section against the source evidence for a abstract_from_evidence task, using the rubric below. Be strict and specific. Punish invented numbers, invented experiments, misattributed figures, and claims that cannot be traced to the provided evidence. Reward outputs whose details are demonstrably present in the evidence.

## Rubric axes (score each 0.0 to 1.0)

- `writing_structure_compliance`
- `evidence_grounding`
- `factual_fidelity`
- `traceability`
- `hallucination_absence`

Axis definitions:

- writing_structure_compliance: Does the output open with the expected section heading and follow a plausible section structure (appropriate level of detail, logical flow, typical subsections for the task family)?
- evidence_grounding: Is every non-trivial claim traceable to specific content in the source evidence? Penalize free-floating claims.
- factual_fidelity: Do quantitative values, qualifiers ("significantly", "modestly"), organisms, time points, sample sizes, and cited figures/tables exactly match the source? Any mismatch is a serious deduction.
- traceability: Are evidence identifiers, section pointers (e.g. "methods_section", "abstract_section"), figure/table references, or accessions cited where useful? 0.0 if there are zero references; 1.0 if they are pervasive and correct.
- hallucination_absence: Is the output free of fabricated content (made-up citations, phantom experiments, invented numerical values)? 1.0 = no hallucinations found; 0.0 = at least one clear fabrication.

## Pass threshold

An axis is considered passing at >= 0.6. overall_pass is true if and only if every axis is at or above that threshold.

## Source evidence

## Methods
The Cancer Genome Atlas (TCGA) database analysis reveals that aberrant expression of SMC4 exhibits a robust prognostic association with metastatic progression. To investigate the function of SMC4, the SMC4 gene is knocked down in RM1-LM cells, a highly metastatic cell clone is developed, using the CRISPR/Cas9 system. The results show that SMC4 knockdown significantly diminished cell proliferation and migration in vitro. Furthermore, in a murine model, RM1-LM cells display higher lung metastasis capabilities than SMC4 knockdown cells.

## Results
2. Results 2.1. High SMC4 Expression Is Associated with Poor Prognosis and the Gleason Grade in Human Prostate Cancer To explore the clinical role of SMC4, we analyzed its expression in various types of tumors using data from The Cancer Genome Atlas (TCGA) database. The findings showed that SMC4 is highly expressed in multiple cancers (Figure S1 , Supporting Information). We further investigated 492 prostate cancer tissues and 152 normal prostate tissues, and the results demonstrated that there was no difference in the expression of SMC4. ( Figure 1 A ). However, survival analyses revealed that overall survival was significantly lower in the high‐SMC4 group compared to the low‐SMC4 group ( p < 0.01) (Figure 1B ). Moreover, patients with higher SMC4 mRNA expression manifested poor disease‐free survival compared with those with lower SMC4 mRNA expression, and results were identical for overall survival ( p < 0.01) (Figure 1C ). Furthermore, our examination of the Oncomine prostate cancer datasets revealed a noteworthy elevation of SMC4 mRNA expression in metastatic prostate cancer compared to that in primary tumors, suggesting an ongoing contribution to the progression of metastasis (Figure 1D–F ). Figure 1 SMC4 expression is upregulated in human prostate cancer and related to the poor prognosis and metastasis. A) Comparison of SMC4 gene expression between prostate cancer tissues and normal tissues in a TCGA dataset. B) Kaplan‐Meier curves of overall survival in TCGA prostate cancer patients with SMC4 high or low expression divided by the median. Data are from the Oncomine database. C) Kaplan‐Meier curves of disease‐free survival in TCGA prostate cancer patients with SMC4 high or low expression divided by the median. Data are from the Oncomine database. D—F) SMC4 mRNA is upregulated in metastases relative to primary tumors in Oncomine prostate cancer datasets (** p < 0.01, **** p < 0.0001 based on the Student's t test; data are presented as means ± SD). G) The mRNA expression in human prostate epithelial and prostate cancer cell lines. H) Western blot showing the expression of SMC4 in human prostate epithelial and prostate cancer cell lines. I) Relative expression of SMC4 mRNA in human prostate epithelial and prostate cancer cell lines. J) IHC staining of SMC4 protein within a human prostate cancer tissue microarray (scale bar represents 200 µm). K) Statistical comparison of SMC4 protein expression between normal and tumor patients. L) Statistical comparison of SMC4 protein expression based on Gleason scores (* p < 0.05, ** p < 0.01 based on Student t test; data represent means ± SD). We measured the expression of SMC4 in human prostate cancer cell lines. The qPCR and western blotting results showed that SMC4 was significantly overexpressed in these cell lines (Figure 1G–I ). IHC results from human prostate cancer tissue microarrays indicated that SMC4 protein expression was elevated in prostate cancer tissues in tandem with increased Gleason grade (Figure 1J–L ). Our findings indicate that outlier expression of SMC4 exhibit a robust prognostic association with metastatic progression, and that the SMC4 prognostic outlier genes continue to occupy roles in metastatic prostate cancer. 2.2. SMC4 Promotes Human Prostate Cancer Cell Proliferation, Migration, and Invasion in Vitro To elucidate the functional roles of SMC4, we employed siRNA‐SMC4 transfection to suppress SMC4 expression in the DU145 and 22RV1 cell lines. Quantitative PCR (qPCR) and Western blotting (WB) confirmed the successful knockdown of SMC4 ( Figure 2 A,B ). Subsequently, we assessed cell proliferation capacity and colony formation ability post‐transfection and observed a significant inhibition of growth upon SMC4 knockdown (Figure 2C–E ). In addition, we performed a Transwell assay to evaluate cellular migratory and invasive capabilities following transfection (Figure 2F ). Notably, DU145 and 22RV1 cells transfected with siRNA displayed lower migration and invasion capabilities than the controls ( P < 0.01, Figure 2G ). Figure 2 SMC4 promotes human prostate cancer cell proliferation, migration, and invasion in vitro. A,B) siRNA‐mediated knockdown of SMC4 in DU145 and 22RV1 cell lines was verified by real‐time PCR and western blotting. C) A CCK8 assay was executed to measure the proliferation of DU145 and 22RV1 cells after SMC4 knockdown. D) A colony‐formation assay showed that the cells’ proliferative capacity was inhibited after SMC4 knockdown. E) Qu...

## Figure captions
1. Figure 1. SMC4 expression is upregulated in human prostate cancer and related to the poor prognosis and metastasis. A) Comparison of SMC4 gene expression between prostate cancer tissues and normal tissues in a TCGA dataset. B) Kaplan‐Meier curves of overall survival in TCGA prostate cancer patients with SMC4 high or low expression divided by the median. Data are from the Oncomine database. C) Kaplan‐Meier curves of disease‐free survival in TCGA prostate cancer patients with SMC4 high or low expression divided by the median. Data are from the Oncomine database. D—F) SMC4 mRNA is upregulated...
2. Figure 2. SMC4 promotes human prostate cancer cell proliferation, migration, and invasion in vitro. A,B) siRNA‐mediated knockdown of SMC4 in DU145 and 22RV1 cell lines was verified by real‐time PCR and western blotting. C) A CCK8 assay was executed to measure the proliferation of DU145 and 22RV1 cells after SMC4 knockdown. D) A colony‐formation assay showed that the cells’ proliferative capacity was inhibited after SMC4 knockdown. E) Quantitative analysis of colony numbers. F) Migration and invasion after siRNA‐mediated knockdown of SMC4 in DU145 and 22RV1 cells. G) Relative analysis of mig...
3. Figure 3. SMC4 knockdown via the CRISPR/Cas9 system inhibits highly metastatic prostate cancer cellular proliferation and colony formation. A) Diagram illustrating the isolation of highly metastatic prostate cancer cells. B) The mRNA level of SMC4 was measured by quantitative real‐time PCR in RM1cells and highly metastatic prostate cancer cells. C) Western blotting results showing SMC4 expression in RM1 cells and highly metastatic prostate cancer cells. D) The relative protein expression of SMC4 in RM1 cells and highly metastatic prostate cancer cells. E) Knockdown of SMC4 was confirmed by...
4. Figure 4. SMC4 knockdown inhibits cell cycle progression and cell migration and invasion, promoting mouse prostate cancer metastasis and progression in vitro. A,B) Flow cytometry and western blot analysis were used to assess cell cycle kinetics. C) Transwell assays were performed to determine cell migration and invasion. D) Relative analysis of migration and invasion. E) Images of wound‐healing assay. F) The area of cell migration into the scratch wound compared with that at 0 h, which was determined as 100% open. ** p < 0.01, *** p < 0.001. Data are shown as the mean ± SD.
5. Figure 5. SMC4 knockdown inhibits highly metastatic prostate cancer cell metastasis and progression in vivo. A) Bioluminescence imaging (BLI) of mouse tumors was measured every 5–7 days, and the images are from day 24th. N (vector) = 11, N (SMC4‐K1/K2) = 10. B) Quantification of tumor photon flux in lung metastases in mice. C) Mouse weights were measured every 2–3 days. D) Kaplan‐Meier curves show mouse survival after inoculation with RM1‐LM‐Vector cells or SMC4‐knockdown cells. E: Percent lung metastasis of RM1‐LM‐Vector cells and SMC4‐knockdown cells after inoculation. F) Mouse lung tissu...
6. Figure 6. Transcriptomic profiling of RM1‐LM and SMC4 knockdown cells. A) Volcano plots show the differential expression of mRNA transcripts between RM1‐LM‐Vector and SMC4‐knockdown cells. Red, gray, and blue represent significantly upregulated, non‐significant, and significantly downregulated mRNAs, respectively. A: RM1‐LM‐Vector cells. B) SMC4‐K1 cells. C: SMC4‐K2 cells. B) GSEA shows significant enrichment of gene‐expression signatures in the cell cycle and chromosomal separation. FDR, false‐discovery rate; normalized ES, normalized enrichment score. C) The top genes in the Kyoto Encyclo...
7. Figure 7. SMC4 interacts with GLUT1 in RM1 cells. A) SMC4‐interacting proteins by LC‐MS/MS analysis were enriched according to Kappa‐statistical similarities. B) SMC4 was labeled with HA, and GLUT1 was labeled with Flag; co‐IP showed that SMC4 interacted with GLUT1. C) Immunofluorescence staining. Scale bars, 2 µm. The areas indicated by boxes are magnified below. D) Comparison of fluorescence intensity profiles. E) Co‐expression of SMC4, BACH1, HK2, PFKFB3, and SLC2A1 in human prostate cancer. Data are from the TCGA dataset. F) The correlation between SMC4 expression and GLUT1, HK2, HIF1a,...
8. Figure 8. The effect of SMC4 on glycolysis rates and mitochondrial respiration. A) ATP production rate assay of RM1‐LM‐Vector and SMC4‐knockdown cells. B—D) SMC4 knockdown inhibits RM1‐LM‐Vector cell glycolytic rates. The basal and compensatory glycolysis rates were significantly lower after SMC4 knockdown. E,F) Mito stress test results demonstrated that cells’ spare respiratory capacity was higher after SMC4 knockdown. G: SLC2A1 was upregulated in metastases versus primary tumors in the Oncomine prostate cancer datasets. H) Western blotting results of mTOR pathway and glycolysis proteins i...

## Candidate output (to be judged)

Abstract

This exploratory study investigates the role of structural maintenance of chromosomes 4 (SMC4) in prostate cancer progression and metastasis. Analysis of The Cancer Genome Atlas (TCGA) data, as detailed in the **results_section**, revealed that high SMC4 expression is associated with significantly poorer overall and disease-free survival in prostate cancer patients, though its level did not differ between bulk tumor and normal tissue. Further **evidence** from Oncomine datasets indicated elevated SMC4 mRNA in metastatic versus primary tumors. In vitro functional assays demonstrated that siRNA-mediated SMC4 knockdown in human prostate cancer cell lines (DU145, 22RV1) suppressed proliferation, migration, and invasion. Using a highly metastatic murine cell line (RM1-LM) developed through in vivo selection, we found SMC4 expression was further elevated. CRISPR/Cas9-mediated SMC4 knockdown in these cells inhibited proliferative and migratory capacities in vitro and attenuated lung metastasis in a murine model, as described in the **abstract_section**. Transcriptomic profiling suggested SMC4 influences cell cycle and chromosomal separation pathways. Furthermore, co-immunoprecipitation and mass spectrometry identified an interaction between SMC4 and the glucose transporter GLUT1, with SMC4 knockdown reducing glycolytic rates. Collectively, the **section_text** and associated figures indicate SMC4 promotes prostate cancer metastasis, potentially through modulating cellular metabolism and cell cycle progression, positioning it as a candidate prognostic marker and therapeutic target.

## Output format

Respond with ONLY a single JSON object. No prose before or after. No markdown code fences. The JSON must match this schema exactly:

{
  "axis_scores": {
    "writing_structure_compliance": <float 0.0-1.0>,
    "evidence_grounding": <float 0.0-1.0>,
    "factual_fidelity": <float 0.0-1.0>,
    "traceability": <float 0.0-1.0>,
    "hallucination_absence": <float 0.0-1.0>
  },
  "axis_rationales": {
    "writing_structure_compliance": "<1-3 sentences>",
    "evidence_grounding": "<1-3 sentences>",
    "factual_fidelity": "<1-3 sentences>",
    "traceability": "<1-3 sentences>",
    "hallucination_absence": "<1-3 sentences>"
  },
  "grounding_issues": [
    "<specific concern citing the exact claim and why it is unsupported or inconsistent with the evidence>"
  ],
  "overall_pass": <true or false>
}